ADGRB1 and leukemia: Critically, combined therapy with JAK3 and MDM2 inhibitors significantly reduced the leukemia burden of these T-ALL in vivo, suggesting a therapeutic role of the BAI1-MDM2-p53 pathway for T-ALL patients with PHF6 and JAK3 comutation [38].